Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Microfluidic Chip Can Diagnose Latent Tuberculosis

By LabMedica International staff writers
Posted on 06 Jun 2012
A microfluidic chip has been developed that can test for latent tuberculosis infection (LTBI) and maybe faster and more reliable than current testing for the disease.

Current tests for LTB are based on detecting the release of interferon-gamma (IFN-γ), a disease-fighting chemical made by cells of the immune system, which commercially available tests require sending samples to a laboratory, and can be used just once.

Biomedical engineers at University of California, Davis (UCD; CA, USA) developed a novel approach for the assay. More...
They coated a gold wafer with short pieces of a single-stranded DNA segment known to stick specifically to IFN-γ. They then mounted the wafer in a chip that has tiny channels for blood samples. If IFN-γ is present in a blood sample, it sticks to the DNA, triggering an electrical signal that can be read by a clinician.

The scientists plan to refine the system so that the microfluidic sensor and electronic readout are integrated on a single chip. An electrochemical biosensor for simple and sensitive detection of IFN-γ will have future applications in immunology, cancer research, and infectious disease monitoring. The team has already conducted testing of blood samples from patients in China and the USA. About one-third of the world's population is infected with the bacteria that cause tuberculosis, a disease that kills an estimated 1.5 million people worldwide every year, according to the US Centers for Disease Control and Prevention (CDC; Atlanta GA, USA).

Most infected people have latent TB, in which the bacteria are kept in check by the immune system. Patients become sick only when the immune system is compromised, enabling the bacteria to become active. People infected with the human immunodeficiency virus (HIV) are at especially high risk. Alexander Revzin, PhD, a professor in the UC Davis Department of Biomedical Engineering and his specialist Ying Liu, PhD, added, "Our assay is cheaper than other interferon-gamma release assays, is reusable, and gives results in real time. If you see that the IFN-γ level is high, you can diagnose latent TB."

Related Links:

University of California at Davis
US Centers for Disease Control and Prevention



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.